Printer Friendly

New Partnership Pairs Sutro Biopharma's Protein Synthesis Technology with Merck's Immunology and Cancer Expertise.

M2 PHARMA-July 26, 2018-New Partnership Pairs Sutro Biopharma's Protein Synthesis Technology with Merck's Immunology and Cancer Expertise

(C)2018 M2 COMMUNICATIONS

- South San Francisco, California-based clinical-stage drug discovery, development and manufacturing company Sutro Biopharma, Inc. has signed a collaboration and licensing agreement with Merck, known as MSD outside the US and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders, the company said.

The research and development activities will leverage Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms, which facilitate precision design and rapid empirical optimisation of protein conjugates, to discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.

Under the agreement, Sutro will be primarily responsible for preclinical research and Merck will gain exclusive worldwide rights to therapeutic candidates derived from the collaboration.

Sutro will receive an upfront payment of USD 60m and is eligible for milestone payments totaling up to USD 1.6bn associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration, as well as tiered royalties on the sale of products.

Sutro Biopharma is a creating a broad variety of next-generation protein therapeutics for oncology based on its proprietary, cell-free protein synthesis platform, XpressCF.

The company designs cytokine-based immuno-oncology therapies, antibody-drug conjugates, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 26, 2018
Words:241
Previous Article:US FDA Grants Approval of Orilissa (elagolix) for Management of Moderate to Severe Pain Associated with Endometriosis.
Next Article:PTC Therapeutics Publishes Data Demonstrating Benefit of Deflazacort in Duchenne Muscular Dystrophy.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |